報價延遲最少15分鐘:2026/04/18 03:05 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.59 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.68/-0.63
|
|
企業價值
87.39M
|
| 資產負債 |
|
每股賬面淨值
0.68
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
29.33K
|
|
每股收益
0.00
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings. |
